Scarica l'app Stockscreener
73.34
0.07%
0.05
Dopo l'orario di chiusura:
75.88
2.54
+3.46%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HALO Giù?
Forum
Previsione
Precedente Chiudi:
$73.29
Aprire:
$73.96
Volume 24 ore:
1.83M
Relative Volume:
0.83
Capitalizzazione di mercato:
$8.58B
Reddito:
$947.36M
Utile/perdita netta:
$392.47M
Rapporto P/E:
24.28
EPS:
3.02
Flusso di cassa netto:
$392.71M
1 W Prestazione:
-5.45%
1M Prestazione:
+0.26%
6M Prestazione:
+14.93%
1 anno Prestazione:
+28.13%
Intervallo 1D:
$73.06
$74.93
Intervallo di 1 settimana:
$73.06
$78.33
Portata 52W:
$42.01
$79.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
Nome
Halozyme Therapeutics Inc
Settore
Industria
Telefono
(858) 794-8889
Indirizzo
12390 EL CAMINO REAL, SAN DIEGO, CA
Confronta HALO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
73.34 | 8.57B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-06 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | Ripresa | Goldman | Neutral |
| 2025-05-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Downgrade | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-06-07 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | Iniziato | TD Cowen | Outperform |
| 2023-07-24 | Downgrade | Goldman | Buy → Neutral |
| 2023-07-24 | Iniziato | H.C. Wainwright | Buy |
| 2023-05-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | Ripresa | Berenberg | Buy |
| 2023-03-16 | Downgrade | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | Ripresa | Morgan Stanley | Overweight |
| 2022-11-28 | Iniziato | Wells Fargo | Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Iniziato | Evercore ISI | Outperform |
| 2021-05-17 | Iniziato | SVB Leerink | Outperform |
| 2021-05-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | Reiterato | The Benchmark Company | Buy |
| 2020-12-17 | Iniziato | Berenberg | Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-07-01 | Iniziato | The Benchmark Company | Buy |
| 2020-02-05 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | Iniziato | Goldman | Buy |
| 2019-11-05 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-10-19 | Ripresa | Piper Jaffray | Neutral |
| 2018-05-11 | Downgrade | Barclays | Equal Weight → Underweight |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2017-10-16 | Reiterato | Piper Jaffray | Overweight |
| 2017-01-06 | Downgrade | Citigroup | Buy → Neutral |
| 2016-11-03 | Iniziato | Deutsche Bank | Buy |
| 2015-12-04 | Iniziato | Wells Fargo | Outperform |
| 2015-11-18 | Iniziato | Citigroup | Buy |
| 2015-09-22 | Iniziato | Barclays | Overweight |
| 2015-06-22 | Reiterato | JP Morgan | Overweight |
| 2015-03-03 | Reiterato | UBS | Buy |
| 2015-02-18 | Reiterato | MLV & Co | Buy |
| 2015-01-08 | Reiterato | MLV & Co | Buy |
Mostra tutto
Halozyme Therapeutics Inc Borsa (HALO) Ultime notizie
Key metrics from Halozyme Therapeutics Inc.’s quarterly dataJuly 2025 Short Interest & Risk Controlled Daily Plans - newser.com
Halozyme: Royalty Harvest Now, Post-2027 Roadmap Still Thin (Maintain Hold) (NASDAQ:HALO) - Seeking Alpha
How geopolitical risks impact Halozyme Therapeutics Inc. (RV7) stockLong Setup & Weekly High Return Stock Opportunities - newser.com
How buybacks impact Halozyme Therapeutics Inc. stock valueMarket Weekly Review & Step-by-Step Trade Execution Guides - newser.com
Pattern recognition hints at Halozyme Therapeutics Inc. upsideM&A Rumor & Fast Entry Momentum Alerts - newser.com
Will Halozyme Therapeutics Inc. (RV7) stock outperform global peersQuarterly Profit Report & Fast Entry Momentum Trade Alerts - newser.com
What analysts say about Halozyme Therapeutics Inc stockPrice Momentum Alerts & Exceptional Return Stocks - earlytimes.in
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View - MSN
Congress Asset Management Co. Sells 297,296 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance
Halozyme Therapeutics, Inc. $HALO Holdings Lowered by Ruffer LLP - MarketBeat
Norden Group LLC Sells 3,457 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics Hits New 52-Week High of $79.31, Up 53% Yearly - Markets Mojo
Benchmark raises Halozyme stock price target to $90 on strong earnings - Investing.com
Halozyme Therapeutics Hits New 52-Week High of $79.46, Up 51.62% - Markets Mojo
Halozyme Therapeutics (HALO): Benchmark Raises Price Target to $90 | HALO Stock News - GuruFocus
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $90.00 at Benchmark - MarketBeat
Zacks Industry Outlook Highlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals and Twist BioScience - The Globe and Mail
Brokerages Set Halozyme Therapeutics, Inc. (NASDAQ:HALO) Target Price at $67.11 - MarketBeat
Halozyme Therapeutics, Inc. $HALO Stock Holdings Lowered by NorthCrest Asset Manangement LLC - MarketBeat
Insider Sell Alert: Nicole Labrosse Sells Shares of Halozyme The - GuruFocus
Shelton Wealth Management LLC Takes $843,000 Position in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Insider Selling: Halozyme Therapeutics (NASDAQ:HALO) CFO Sells 2,227 Shares of Stock - MarketBeat
Livforsakringsbolaget Skandia Omsesidigt Buys 44,700 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics and Synopsys have been highlighted as Zacks Bull and Bear of the Day - Yahoo Finance
5 Biotech Stocks Worth Adding to Your Portfolio Now - Yahoo Finance
Bull of the Day: Halozyme Therapeutics (HALO) - The Globe and Mail
Halozyme Therapeutics, Inc. $HALO Shares Purchased by Redhawk Wealth Advisors Inc. - MarketBeat
Those Who Invested in Halozyme Therapeutics (NASDAQ:HALO) Five Years Ago Are up 200% - 富途牛牛
Halozyme Therapeutics Hits New 52-Week High of $77.95, Surges 52% - Markets Mojo
Halozyme Therapeutics stock price target raised to $85 at H.C. Wainwright - Investing.com
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $85.00 at HC Wainwright - MarketBeat
Halozyme Therapeutics (HALO) Target Price Raised by HC Wainwrigh - GuruFocus
Halozyme Therapeutics, Inc. (HALO): Investor Outlook on a Biotech Powerhouse with a 40.8% Revenue Growth - DirectorsTalk Interviews
Swedbank AB Sells 100,100 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Hits New 52-Week HighWhat's Next? - MarketBeat
Livforsakringsbolaget Skandia Omsesidigt Sells 38,210 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Financiere des Professionnels Fonds d investissement inc. Makes New $527,000 Investment in Halozyme Therapeutics, Inc. $HALO - MarketBeat
New Highs: Will Halozyme Therapeutics Inc. benefit from seasonality2025 Technical Patterns & Smart Money Movement Tracker - خودرو بانک
Strs Ohio Buys Shares of 30,000 Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics stock hits all-time high at 77.6 USD By Investing.com - Investing.com Nigeria
Halozyme Therapeutics stock hits all-time high at 77.6 USD - Investing.com India
FOMO Trade: What drives Halozyme Therapeutics Inc.’s stock price2025 Market WrapUp & Reliable Momentum Entry Alerts - خودرو بانک
Swedbank AB Sells 26,100 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Market Catalysts: What is PSNY’s book value per share2025 Key Highlights & Advanced Technical Analysis Signals - khodrobank.com
Halozyme Therapeutics (HALO) Is Up 2.63% in One Week: What You Should Know - sharewise.com
Halozyme Therapeutics, Inc. (HALO) Hikes 2025 Guidance on ENHANZE Demand - MSN
Halozyme Therapeutics Inc Azioni (HALO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.36%
1.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):